Physician profile
Alyssa Horowitz
NPI 1013943901
$1,354.61
in general payments reported to CMS, 2019-2025
14 companies · $84.04 in 2025
The $84.04 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $651 · 2021: $116 · 2022: $132 · 2023: $102 · 2024: $82.44 · 2025: $84.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $268.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $666.00 | 2019-2022 | |
| Allergan, INC. | $170.25 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $154.45 | 2021-2025 | |
| Pfizer INC. | $66.05 | 2023-2024 | |
| Roche Diagnostics Corporation | $62.65 | 2019-2021 | |
| Abbvie INC. | $57.17 | 2020-2022 | |
| Therapeuticsmd, INC. | $52.12 | 2021-2022 | |
| Exeltis, USA INC. | $30.30 | 2024-2025 | Slynd |
| Organon LLC | $24.71 | 2024 | |
| Dysis Medical, INC. | $21.54 | 2021 | |
| Millicent US INC | $18.45 | 2025 | Femlyv |
| Shield Therapeutics INC | $16.90 | 2025 | |
| Myovant Sciences INC. | $14.02 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Horowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.